Bristol-Myers Squibb and Pfizer said information from 15 abstracts will be presented at the European Society of Cardiology Congress 2017, running through Aug. 30 in Barcelona, Spain.
Information from EMANATE testing will be disclosed in the late-breaking science hot-line session as well as at the European Society of Cardiology press conference, a Pfizer release said. The EMANATE testing is phase 4 study observing how Eliquis works with patients with non-valvular atrial fibrillation who anticipate having cardioversion to make their heart beat regular again.
Information on ACROPOLIS testing will also be unveiled at the conference. This testing is looking at how Eliquis would be for doctors to regularly give to patients, especially those battling non-valvular atrial fibrillation who face a good probability that they'll suffer a stroke or have significant bleeding because of their age, the release said.
